Resolution of praziquantel.

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Pharmacology

Background:

• Praziquantel is the primary treatment for schistosomiasis.
• The current drug is a racemate, containing both active and inactive enantiomers.
• The inactive enantiomer contributes to side effects and bitter taste.

Purpose of the Study:

• To develop methods for producing single-enantiomer praziquantel.
• To enable cost-effective, large-scale synthesis of the active enantiomer.
• To facilitate research into praziquantel's mechanism of action.

Main Methods:

• Two distinct resolution approaches were identified for enantiopure praziquantel production.
• Method 1: Hydrolysis of commercial praziquantel to an intermediate amine, followed by resolution with a tartaric acid derivative.
• Method 2: Resolution of a different intermediate using tartaric acid itself.

Main Results:

• Both identified resolution procedures show potential for scalable production.
• The methods are economically viable for producing enantiopure praziquantel at a low cost.
• These procedures can also be used for smaller-scale synthesis for research.

Conclusions:

• The developed methods offer a promising route to enantiopure praziquantel.
• Large-scale, affordable production of the active enantiomer is feasible.
• Enantiopure praziquantel can be produced for research, aiding in mechanism of action studies.